• Je něco špatně v tomto záznamu ?

Synthesis and Cytotoxic Activity of Triterpenoid Thiazoles Derived from Allobetulin, Methyl Betulonate, Methyl Oleanonate, and Oleanonic Acid

L. Borkova, R. Adamek, P. Kalina, P. Drašar, P. Dzubak, S. Gurska, J. Rehulka, M. Hajduch, M. Urban, J. Sarek,

. 2017 ; 12 (5) : 390-398. [pub] 20170127

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023363

A total of 41 new triterpenoids were prepared from allobetulone, methyl betulonate, methyl oleanonate, and oleanonic acid to study their influence on cancer cells. Each 3-oxotriterpene was brominated at C2 and substituted with thiocyanate; subsequent cyclization with the appropriate ammonium salts gave N-substituted thiazoles. All compounds were tested for their in vitro cytotoxic activity on eight cancer cell lines and two non-cancer fibroblasts. 2-Bromoallobetulone (2 b) methyl 2-bromobetulonate (3 b), 2-bromooleanonic acid (5 b), and 2-thiocyanooleanonic acid (5 c) were best, with IC50 values less than 10 μm against CCRF-CEM cells (e.g., 3 b: IC50 =2.9 μm) as well as 2'-(diethylamino)olean-12(13)-eno[2,3-d]thiazole-28-oic acid (5 f, IC50 =9.7 μm) and 2'-(N-methylpiperazino)olean-12(13)-eno[2,3-d]thiazole-28-oic acid (5 k, IC50 =11.4 μm). Compound 5 c leads to the accumulation of cells in the G2 phase of the cell cycle and inhibits RNA and DNA synthesis significantly at 1×IC50 . The G2 /M cell-cycle arrest probably corresponds to the inhibition of DNA/RNA synthesis, similar to the mechanism of action of actinomycin D. Compound 5 c is new, active, and nontoxic; it is therefore the most promising compound in this series for future drug development. Methyl 2-bromobetulonate (3 b) and methyl 2-thiocyanometulonate (3 c) were found to inhibit nucleic acid synthesis only at 5×IC50 . We assume that in 3 b and 3 c (unlike in 5 c), DNA/RNA inhibition is a nonspecific event, and an unknown primary cytotoxic target is activated at 1×IC50 or lower concentration.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023363
003      
CZ-PrNML
005      
20200728083835.0
007      
ta
008      
170720s2017 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cmdc.201600626 $2 doi
035    __
$a (PubMed)28084676
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Borkova, Lucie $u Department of Organic Chemistry, Faculty of Science, Palacky University in Olomouc, 17. listopadu 1192/12, 771 46, Olomouc, Czech Republic.
245    10
$a Synthesis and Cytotoxic Activity of Triterpenoid Thiazoles Derived from Allobetulin, Methyl Betulonate, Methyl Oleanonate, and Oleanonic Acid / $c L. Borkova, R. Adamek, P. Kalina, P. Drašar, P. Dzubak, S. Gurska, J. Rehulka, M. Hajduch, M. Urban, J. Sarek,
520    9_
$a A total of 41 new triterpenoids were prepared from allobetulone, methyl betulonate, methyl oleanonate, and oleanonic acid to study their influence on cancer cells. Each 3-oxotriterpene was brominated at C2 and substituted with thiocyanate; subsequent cyclization with the appropriate ammonium salts gave N-substituted thiazoles. All compounds were tested for their in vitro cytotoxic activity on eight cancer cell lines and two non-cancer fibroblasts. 2-Bromoallobetulone (2 b) methyl 2-bromobetulonate (3 b), 2-bromooleanonic acid (5 b), and 2-thiocyanooleanonic acid (5 c) were best, with IC50 values less than 10 μm against CCRF-CEM cells (e.g., 3 b: IC50 =2.9 μm) as well as 2'-(diethylamino)olean-12(13)-eno[2,3-d]thiazole-28-oic acid (5 f, IC50 =9.7 μm) and 2'-(N-methylpiperazino)olean-12(13)-eno[2,3-d]thiazole-28-oic acid (5 k, IC50 =11.4 μm). Compound 5 c leads to the accumulation of cells in the G2 phase of the cell cycle and inhibits RNA and DNA synthesis significantly at 1×IC50 . The G2 /M cell-cycle arrest probably corresponds to the inhibition of DNA/RNA synthesis, similar to the mechanism of action of actinomycin D. Compound 5 c is new, active, and nontoxic; it is therefore the most promising compound in this series for future drug development. Methyl 2-bromobetulonate (3 b) and methyl 2-thiocyanometulonate (3 c) were found to inhibit nucleic acid synthesis only at 5×IC50 . We assume that in 3 b and 3 c (unlike in 5 c), DNA/RNA inhibition is a nonspecific event, and an unknown primary cytotoxic target is activated at 1×IC50 or lower concentration.
650    _2
$a protinádorové látky $x chemická syntéza $x chemie $x toxicita $7 D000970
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a kontrolní body fáze G2 buněčného cyklu $x účinky léků $7 D059565
650    _2
$a lidé $7 D006801
650    _2
$a kontrolní body M fáze buněčného cyklu $x účinky léků $7 D059566
650    _2
$a kyselina olenalová $x analogy a deriváty $x chemie $7 D009828
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a thiazoly $x chemická syntéza $x chemie $x toxicita $7 D013844
650    _2
$a triterpeny $x chemie $7 D014315
655    _2
$a časopisecké články $7 D016428
700    1_
$a Adamek, Richard $u Department of Organic Chemistry, Faculty of Science, Palacky University in Olomouc, 17. listopadu 1192/12, 771 46, Olomouc, Czech Republic. $7 gn_A_00001310
700    1_
$a Kalina, Petr $u Department of Chemistry of Natural Compounds, Faculty of Science, University of Chemistry and Technology, Technicka 5, 166 28, Prague, Czech Republic.
700    1_
$a Drašar, Pavel $u Department of Chemistry of Natural Compounds, Faculty of Science, University of Chemistry and Technology, Technicka 5, 166 28, Prague, Czech Republic.
700    1_
$a Dzubak, Petr $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00, Olomouc, Czech Republic.
700    1_
$a Gurska, Sona $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00, Olomouc, Czech Republic.
700    1_
$a Rehulka, Jiri $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00, Olomouc, Czech Republic.
700    1_
$a Hajduch, Marian $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00, Olomouc, Czech Republic.
700    1_
$a Urban, Milan $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00, Olomouc, Czech Republic. $7 xx0117688
700    1_
$a Sarek, Jan $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00, Olomouc, Czech Republic.
773    0_
$w MED00173270 $t ChemMedChem $x 1860-7187 $g Roč. 12, č. 5 (2017), s. 390-398
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28084676 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20200728083832 $b ABA008
999    __
$a ok $b bmc $g 1239044 $s 984276
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 12 $c 5 $d 390-398 $e 20170127 $i 1860-7187 $m ChemMedChem $n ChemMedChem $x MED00173270
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...